[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide].
A 47-year-old female underwent mastectomy after neo-adjuvant chemotherapy including an anthracycline agent for advanced breast cancer. She developed a pleural metastasis on 16 months later, which was refractory to intrathoracic cisplatinum administration and intravenous Docetaxel therapy. Brain metastases were also found. We therefore treated her with whole brain radiation therapy and oral chemotherapy with 5'-DFUR and cyclophosphamide. This combination therapy produced a marked decrease in each metastasis. The adverse effects were not remarkable. This regimen may play an important role not only from the standpoint of its effectiveness against tumor growth but also the quality of life of the patient.
Kusama
M
M
3rd Dept. of Surgery, Tokyo Medical University.
Kaise
H
H
Nakayama
S
S
Yoneda
K
K
Aoki
T
T
Koyanagi
Y
Y
Matsunaga
T
T
Nakamura
Y
Y
D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D016371:Cranial Irradiation; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000494:pharmacology; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000556:secondary*; D011788:Quality of Life; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D005467:Floxuridine; D000077143:Docetaxel; D003520:Cyclophosphamide; D017239:Paclitaxel; C025034:doxifluridine